[go: up one dir, main page]

AR017236A1 - Compuestos biciclo [2.2.1] heptanos, composiciones farmaceuticas, procedimientos para tratar - Google Patents

Compuestos biciclo [2.2.1] heptanos, composiciones farmaceuticas, procedimientos para tratar

Info

Publication number
AR017236A1
AR017236A1 ARP990101118A ARP990101118A AR017236A1 AR 017236 A1 AR017236 A1 AR 017236A1 AR P990101118 A ARP990101118 A AR P990101118A AR P990101118 A ARP990101118 A AR P990101118A AR 017236 A1 AR017236 A1 AR 017236A1
Authority
AR
Argentina
Prior art keywords
alkyl
compounds
optionally substituted
heteroaryl
aryl
Prior art date
Application number
ARP990101118A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR017236A1 publication Critical patent/AR017236A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/46Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C229/50Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms being part of the same condensed ring system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/36Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/42Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Addiction (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

La presente invencion se refiere a compuestos de formula IV en la que n es 0-6; X es CH2, CH2CH2 u oxígeno;Z es CHR2 o NR2;R1 y R2 se seleccionan, de formaindependiente, de H,alquilo C1-6, arilo y heteroarilo seleccionándose dicho arilo de fenilo y naftilo y seleccionándose dicho heteroarilo de anillosheterocíclicos aromáticos de 5 y 6 eslabones que contienen de 1 a c4 heteroátomos seleccionados independientemente, de nitrogeno, oxígeno y azufre y pudiendoestar dichos restos de arilo y heteroarilo opcionalmente sustituidos con uno o más sustituyentes,que se seleccionan,independientemente,de halogeno, S(alquiloC1-6), -S(O)(alquilo C1-6), -S(O)2-(alquilo C1-6), alquilo C1-6 opcionalmente sustituido con desde uno a siete átomos de fluor, alcoxi C1-6 opcionalmentesustituido con desde uno a siete átomos de fluor, amino, nitro, carboxi, -CO2(alquilo C1-C6), (alquil C1-6)amino, di(alquil C1-6)aminofenoxi, anilino yfeniltio; y R7 es hidrogeno, alquilo C1-6 bencilo a condicion de que ninguno de dichos restos heteroarilo contenga más de un átomo de oxígeno en el anillo omás de un átomo de azufre en el anillo, a composiciones farmacéuticas que contienen dichos compuestos y al uso de tales compuestos para tratar trastornosneurologicos y psiquiátricos.
ARP990101118A 1998-03-17 1999-03-15 Compuestos biciclo [2.2.1] heptanos, composiciones farmaceuticas, procedimientos para tratar AR017236A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7834698P 1998-03-17 1998-03-17

Publications (1)

Publication Number Publication Date
AR017236A1 true AR017236A1 (es) 2001-08-22

Family

ID=22143450

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990101118A AR017236A1 (es) 1998-03-17 1999-03-15 Compuestos biciclo [2.2.1] heptanos, composiciones farmaceuticas, procedimientos para tratar

Country Status (40)

Country Link
US (1) US6136861A (es)
EP (1) EP1064256B1 (es)
JP (1) JP3665567B2 (es)
KR (1) KR100372981B1 (es)
CN (1) CN1231461C (es)
AP (1) AP1116A (es)
AR (1) AR017236A1 (es)
AT (1) ATE272608T1 (es)
AU (1) AU753422B2 (es)
BG (1) BG104837A (es)
BR (1) BR9908850A (es)
CA (1) CA2321639C (es)
CO (1) CO5090835A1 (es)
CZ (1) CZ20003355A3 (es)
DE (1) DE69919142T2 (es)
DZ (1) DZ2745A1 (es)
EA (1) EA003946B1 (es)
ES (1) ES2224604T3 (es)
GT (1) GT199900040A (es)
HR (1) HRP20000611A2 (es)
HU (1) HUP0101031A3 (es)
ID (1) ID25651A (es)
IL (1) IL138342A0 (es)
IS (1) IS5592A (es)
MA (1) MA26614A1 (es)
MY (1) MY121047A (es)
NO (1) NO20004626L (es)
NZ (1) NZ506227A (es)
OA (1) OA11488A (es)
PE (1) PE20000339A1 (es)
PL (1) PL343278A1 (es)
PT (1) PT1064256E (es)
SK (1) SK13532000A3 (es)
TN (1) TNSN99039A1 (es)
TR (1) TR200002671T2 (es)
TW (1) TW509667B (es)
UA (1) UA53781C2 (es)
WO (1) WO1999047490A1 (es)
YU (1) YU53700A (es)
ZA (1) ZA992094B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6555564B1 (en) * 1999-03-04 2003-04-29 The Board Of Trustees Of The University Of Illinois Neuropharmacological treatments of sleep-related breathing disorders
US6313159B1 (en) 1999-08-20 2001-11-06 Guilford Pharmaceuticals Inc. Metabotropic glutamate receptor ligand derivatives as naaladase inhibitors
UA73981C2 (en) * 2000-03-10 2005-10-17 Merck Patent Gmbh (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane for treatment of extrapyramidal movement disorders (variants), pharmaceutical composition and kit
CA2442717A1 (en) * 2001-03-15 2002-09-26 Saegis Pharmaceuticals, Inc. Methods for restoring cognitive function following systemic stress
US6750364B2 (en) * 2001-06-29 2004-06-15 Wyeth Bridged tricyclic analogs of 2-(carboxycyclopropyl)glycine as inhibitors of glutamate transport
US6689905B2 (en) 2001-06-29 2004-02-10 Wyeth Stereoisomers of 3-aminotricyclo[2.2.1.0(2.6)]heptane-1,3-dicarboxylic acid
US6689904B2 (en) 2001-06-29 2004-02-10 Wyeth Bridged tricyclic analogs of 2-(carboxycyclopropyl)glycine
US6562816B2 (en) 2001-08-24 2003-05-13 Pharmacia & Upjohn Company Substituted-heteroaryl-7-aza[2.2.1]bicycloheptanes for the treatment of disease
US7232798B2 (en) * 2001-11-13 2007-06-19 Tran Loi H Neuroprotection and neuroegenisis by administering cyclic prolyl glycine
FR2872045B1 (fr) * 2004-06-28 2006-09-29 Centre Nat Rech Scient Cnrse Medicaments pour le traitement specifique de symptomes de la maladie de parkinson
TWI417095B (zh) * 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc 1,4-二取代之3-氰基-吡啶酮衍生物及其作為mGluR2-受體之正向異位性調節劑之用途
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) * 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
AU2008299921B2 (en) 2007-09-13 2012-03-01 Concert Pharmaceuticals, Inc. Synthesis of deuterated catechols and benzo[d][1,3] dioxoles and derivatives thereof
EP2203439B1 (en) 2007-09-14 2011-01-26 Ortho-McNeil-Janssen Pharmaceuticals, Inc. 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h, 1'h-ý1, 4'¨bipyridinyl-2'-ones
AU2008297877C1 (en) * 2007-09-14 2013-11-07 Addex Pharma S.A. 1,3-disubstituted-4-phenyl-1 H-pyridin-2-ones
CN101848893B (zh) 2007-09-14 2012-06-06 奥梅-杨森制药有限公司 1,3-二取代的4-(芳基-x-苯基)-1h-吡啶-2-酮
CN101861316B (zh) * 2007-11-14 2013-08-21 奥梅-杨森制药有限公司 咪唑并[1,2-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
MX2011002042A (es) 2008-09-02 2011-06-20 Ortho Mcneil Janssen Pharm Derivados de 3-azabiciclo[3.1.o]hexilo como moduladores de los receptores del glutamato metabotropico.
ES2466341T3 (es) 2008-10-16 2014-06-10 Janssen Pharmaceuticals, Inc. Derivados de indol y benzomorfolina como moduladores de receptores de glutamato metabotrópicos
WO2010060589A1 (en) 2008-11-28 2010-06-03 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
JP5707390B2 (ja) 2009-05-12 2015-04-30 ジャンセン ファーマシューティカルズ, インコーポレイテッド 1,2,4−トリアゾロ[4,3−a]ピリジン誘導体およびmGluR2受容体の正のアロステリック調節因子としてのその使用
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
EP2430022B1 (en) 2009-05-12 2013-11-20 Janssen Pharmaceuticals, Inc. 1,2,4-Triazolo[4,3-a]pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
WO2012062750A1 (en) 2010-11-08 2012-05-18 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
CA2814998C (en) 2010-11-08 2019-10-29 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
EP2661435B1 (en) 2010-11-08 2015-08-19 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
AR083845A1 (es) 2010-11-18 2013-03-27 Lilly Co Eli COMPUESTOS 3-FENILSULFANILMETIL-BICICLO[3.1.0]HEXANO 4-SUSTITUIDOS COMO ANTAGONISTAS DE mGluR2/3
JP5870111B2 (ja) 2010-11-18 2016-02-24 イーライ リリー アンド カンパニー mGluR2/3アンタゴニストとしての4−置換−3−ベンジルオキシ−ビシクロ[3.1.0]ヘキサン化合物
JP6506248B2 (ja) 2013-03-14 2019-04-24 ゾーン・ロイヤリティズ・アンド・マイルストーンズ・エルエルシー 二環式鎮痛化合物
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
KR102380609B1 (ko) 2013-12-12 2022-03-30 리커리엄 아이피 홀딩스, 엘엘씨 바이사이클릭 알킬 화합물 및 합성
ME03518B (me) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena
AU2015208233B2 (en) 2014-01-21 2019-08-29 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
US10654812B2 (en) 2014-03-07 2020-05-19 Recurium Ip Holdings Llc Propellane derivates and synthesis
KR20170048588A (ko) 2014-09-17 2017-05-08 카리라 파마슈티컬스, 아이앤씨. 바이사이클릭 화합물
US20190060257A1 (en) * 2016-03-16 2019-02-28 Zeno Royalties & Milestones, LLC Analgesic compounds
MX389668B (es) 2017-05-15 2025-03-20 Recurium Ip Holdings Llc Compuestos biciclo[1.1.1]pentilo sustituidos y uso de los mismos para el tratamiento del dolor y fiebre.
JP7699378B2 (ja) 2018-05-15 2025-06-27 ハン ロイ トラン ロイド 軽度の認知障害、抑うつ、および精神障害の治療のための治療薬組成物およびその使用方法
KR102157141B1 (ko) 2018-11-27 2020-09-17 주식회사 파미니티 으아리 추출물을 유효 성분으로 포함하는 인지 기능 개선용 조성물
KR102172916B1 (ko) 2018-12-07 2020-11-02 주식회사 파미니티 실크 펩타이드 및 천연 추출물을 포함하는 인지 기능 개선용 조성물
US10844380B1 (en) 2019-06-17 2020-11-24 Biorchestra Co., Ltd. Uses for prevention or treatment of brain diseases using microrna
US11198908B2 (en) 2019-06-17 2021-12-14 Biorchestra Co., Ltd. Method for diagnosis of Alzheimer's disease using microRNA

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0762877T3 (da) * 1994-06-03 2001-07-16 Thejmde Trust Meta-substituerede arylalkylaminer og terapeutiske og diagnostiske anvendelser deraf
PL182285B1 (pl) * 1994-08-12 2001-12-31 Lilly Co Eli Syntetyczne aminokwasy oraz ich estry i srodki farmaceutyczne je zawierajace PL PL PL PL PL PL PL
GB9605429D0 (en) * 1995-11-16 1996-05-15 Lilly Co Eli Excitatory amino acid receptor antagonists
JP2000500752A (ja) * 1995-11-16 2000-01-25 イーライ・リリー・アンド・カンパニー 興奮性アミノ酸受容体アンタゴニスト

Also Published As

Publication number Publication date
HRP20000611A2 (en) 2001-04-30
PL343278A1 (en) 2001-08-13
AU2540999A (en) 1999-10-11
NO20004626L (no) 2000-11-13
KR100372981B1 (ko) 2003-02-25
AP1116A (en) 2002-10-21
DE69919142T2 (de) 2005-01-20
PT1064256E (pt) 2004-10-29
BG104837A (bg) 2001-07-31
JP2002506847A (ja) 2002-03-05
AP9901482A0 (en) 1999-03-31
IL138342A0 (en) 2001-10-31
CA2321639A1 (en) 1999-09-23
EA200000842A1 (ru) 2001-04-23
TW509667B (en) 2002-11-11
PE20000339A1 (es) 2000-05-13
CA2321639C (en) 2005-08-02
CZ20003355A3 (cs) 2002-05-15
MY121047A (en) 2005-12-30
JP3665567B2 (ja) 2005-06-29
OA11488A (en) 2004-05-07
IS5592A (is) 2000-08-18
UA53781C2 (uk) 2003-02-17
CN1293655A (zh) 2001-05-02
BR9908850A (pt) 2000-11-21
YU53700A (sh) 2002-11-15
GT199900040A (es) 2000-09-06
EP1064256B1 (en) 2004-08-04
HUP0101031A3 (en) 2003-05-28
CN1231461C (zh) 2005-12-14
ATE272608T1 (de) 2004-08-15
EA003946B1 (ru) 2003-10-30
DE69919142D1 (de) 2004-09-09
MA26614A1 (fr) 2004-12-20
KR20010041951A (ko) 2001-05-25
WO1999047490A1 (en) 1999-09-23
DZ2745A1 (fr) 2003-09-08
EP1064256A1 (en) 2001-01-03
HUP0101031A2 (hu) 2001-08-28
TR200002671T2 (tr) 2000-12-21
US6136861A (en) 2000-10-24
ES2224604T3 (es) 2005-03-01
SK13532000A3 (sk) 2002-07-02
AU753422B2 (en) 2002-10-17
ZA992094B (en) 2000-11-28
NZ506227A (en) 2003-06-30
NO20004626D0 (no) 2000-09-15
CO5090835A1 (es) 2001-10-30
TNSN99039A1 (fr) 2005-11-10
ID25651A (id) 2000-10-19

Similar Documents

Publication Publication Date Title
AR017236A1 (es) Compuestos biciclo [2.2.1] heptanos, composiciones farmaceuticas, procedimientos para tratar
DK0417584T3 (da) N-Substituerede 4-pyrimidinaminer og -pyrimidindiaminer, fremgangsmåde til deres fremstilling og deres anvendelser som læge
HUP9901113A1 (hu) Herbicid hatású és növényi növekedést szabályozó hatású 2-amino-4-biciklo-amino-1,3,5-triazinok
DK0790987T3 (da) Aminotetrazol-derivater, der er anvendelige som nitrogenoxidsynthaseinhibitorer
PT1052254E (pt) Derivados heterocíclicos azotados e medicamento dos mesmos
NO20045528L (no) MHC1R-antagonister
NO953305D0 (no) Antranilsyrederivat
ATE244227T1 (de) 4,4'-diaminostilben-2,2'-disulfonsäurederivate
CY1105899T1 (el) Πυριδινοϋλοπιπepιδινες ως 5-ht1f αγωνιστες
ATE353870T1 (de) Dibenzylaminverbindung und deren medizinische verwendung
YU57603A (sh) Inhibitori fosfodiesteraze 4
KR880001576A (ko) 아미드 유도체
NO20013254D0 (no) Nye difenylureaforbindelser, fremgangsmåte ved deres fremstilling og farmasöytiske samensetninger som inneholder dem
MY157373A (en) Carbamate compounds for use in preventing or treating movement disorders
PT98747A (pt) Processo para a preparacao de 6,7-dihidro-3-fenil-1-1,2-benzisoxazol-4(5h)-onase -ois e de composicoes farmaceuticas que os contem
ID23954A (id) Tetrahidrogama-karbolin
AR018596A1 (es) Compuestos azapoliciclicos fusionados con arilo utiles en el tratamiento de desordenes neurologicos y fisiologicos, composiciones farmaceuticas,metodos de tratamiento que los utilizan
JO2235B1 (en) Derivatives of phenyl
PT1399144E (pt) Compostos carbamato para utilizacao na prevencao ou tratamento de disturbios de ansiedade
DK498889D0 (da) Substituerede aromatiske forbindelser med virkning paa centralnervesystemet
DK0458234T3 (da) 3-[1-Thiazolidinylbutyl-4-piperazinyl]-1H-indazoler, en fremgangsmåde til deres fremstilling og deres anvendelse som lægemi
BR9600979A (pt) Composto processo para combater fungos fitopatogênicos composição fungicida e processo de preparação de um composto
ID26809A (id) Senyawa-senyawa turunan sianoiminokuinoksalin
ECSP003381A (es) Derivados de bifenil

Legal Events

Date Code Title Description
FB Suspension of granting procedure